As of 2025-12-15, the Relative Valuation of Arbutus Biopharma Corp (ABUS) is (3.76) USD. This relative valuation is based on P/E multiples. With the latest stock price at 4.71 USD, the upside of Arbutus Biopharma Corp based on Relative Valuation is -179.8%.
The range of the Relative Valuation is (2.99) - (4.06) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 13.6x - 18.5x | 17.0x |
| Forward P/E multiples | 9.5x - 20.7x | 17.2x |
| Fair Price | (2.99) - (4.06) | (3.76) |
| Upside | -163.5% - -186.3% | -179.8% |
| Date | P/E |
| 2025-12-05 | -20.11 |
| 2025-12-04 | -20.06 |
| 2025-12-03 | -20.15 |
| 2025-12-02 | -18.97 |
| 2025-12-01 | -19.15 |
| 2025-11-28 | -20.06 |
| 2025-11-26 | -20.06 |
| 2025-11-25 | -19.65 |
| 2025-11-24 | -19.42 |
| 2025-11-21 | -19.61 |
| 2025-11-20 | -19.11 |
| 2025-11-19 | -19.42 |
| 2025-11-18 | -20.24 |
| 2025-11-17 | -20.65 |
| 2025-11-14 | -20.56 |
| 2025-11-13 | -20.74 |
| 2025-11-12 | -22.02 |
| 2025-11-11 | -21.43 |
| 2025-11-10 | -20.88 |
| 2025-11-07 | -20.47 |
| 2025-11-06 | -20.20 |
| 2025-11-05 | -20.97 |
| 2025-11-04 | -20.47 |
| 2025-11-03 | -20.83 |
| 2025-10-31 | -21.52 |
| 2025-10-30 | -22.02 |
| 2025-10-29 | -20.97 |
| 2025-10-28 | -20.83 |
| 2025-10-27 | -20.33 |
| 2025-10-24 | -19.83 |
| 2025-10-23 | -19.47 |
| 2025-10-22 | -20.15 |
| 2025-10-21 | -20.38 |
| 2025-10-20 | -20.70 |
| 2025-10-17 | -20.06 |
| 2025-10-16 | -20.52 |
| 2025-10-15 | -20.33 |
| 2025-10-14 | -19.29 |
| 2025-10-13 | -19.47 |
| 2025-10-10 | -18.70 |
| 2025-10-09 | -19.42 |
| 2025-10-08 | -19.02 |
| 2025-10-07 | -19.52 |
| 2025-10-06 | -19.74 |
| 2025-10-03 | -19.92 |
| 2025-10-02 | -20.43 |
| 2025-10-01 | -20.88 |
| 2025-09-30 | -20.65 |
| 2025-09-29 | -20.29 |
| 2025-09-26 | -20.06 |